WH002
/ Wehand-Bio Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 10, 2026
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=40 | Completed | Sponsor: Beijing Wehand-Bio Pharmaceutical Co., Ltd | Phase classification: P1 ➔ P2
Phase classification • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR
January 21, 2026
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Beijing Wehand-Bio Pharmaceutical Co., Ltd | Not yet recruiting ➔ Completed
Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR
1 to 2
Of
2
Go to page
1